Cloxazolam API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Cloxazolam API 24166-13-0?
- Description:
- Here you will find a list of producers, manufacturers and traders of Cloxazolam. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Cloxazolam
- Synonyms:
- Cloxazolazepam
- Cas Number:
- 24166-13-0
- DrugBank number:
- DB01553
- Unique Ingredient Identifier:
- GYL649Z0HY
About Cloxazolam
Want to know more about Cloxazolam? Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly for anti-anxiety. The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis. As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness.
You can find more info about this product by clicking on the DB ID above.
Cloxazolam is a type of Anxiolytics
Anxiolytics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are substances utilized in the development of drugs aimed at treating anxiety disorders. Anxiety disorders are prevalent mental health conditions characterized by excessive worry, fear, and unease. Anxiolytics work by modulating certain neurotransmitters in the brain, such as gamma-aminobutyric acid (GABA), which plays a crucial role in reducing neuronal excitability and inducing a calming effect.
These pharmaceutical APIs have revolutionized the management of anxiety disorders, providing relief to millions of individuals worldwide. Anxiolytics can be further classified into various subcategories based on their mechanism of action, including benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others.
Benzodiazepines, the most commonly prescribed anxiolytics, enhance the activity of GABA receptors, thereby producing sedative and hypnotic effects. SSRIs and SNRIs, on the other hand, primarily work by increasing the availability of serotonin and norepinephrine, respectively, in the brain, leading to a positive impact on mood and anxiety.
The development and production of anxiolytics involve stringent quality control measures to ensure their safety and efficacy. Pharmaceutical companies adhere to Good Manufacturing Practices (GMP) guidelines and conduct thorough preclinical and clinical trials to evaluate the compound's pharmacokinetics, efficacy, and adverse effects.
In conclusion, anxiolytics are a crucial category of pharmaceutical APIs used to address anxiety disorders. Through their modulation of neurotransmitters and receptors in the brain, these medications effectively alleviate symptoms and improve the quality of life for individuals affected by anxiety.
